Brief description of the medication guide for neratinib

Neratinib (generic name: neratinib, trade name: He Li'an) is a key anti-tumor drug, especially used to treat HER2 positive breast cancer patients. The drug is widely used worldwide. To ensure patients can use this medicine safely and effectively, the following is a concise medication guide.

1. Indications, usage and dosage

Neratinib is suitable for patients with HER2-positive early breast cancer who have completed standard trastuzumab adjuvant therapy but whose disease has not progressed and who have high-risk factors. The drug is also indicated in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more anti-HER2-based regimens in the metastatic setting. The recommended daily dose is 240mg (i.e. 6 tablets 40mg tablets). It is recommended to take it with meals and strictly follow the doctor's treatment time guidance. Patients should try to take their medications at the same time every day to ensure the stability of drug concentrations.

2. Diarrhea prevention measures

Diarrhea is a common side effect of neratinib. To prevent severe diarrhea, it is recommended to start preventive use of the antidiarrheal drug loperamide 56 days before taking the medication and strictly follow the doctor's instructions. If diarrhea symptoms are severe, seek medical attention promptly and adjust the antidiarrheal treatment plan.

3. Adverse reaction monitoring and treatment

In addition to diarrhea, neratinib may also cause nausea, vomiting, abdominal pain, fatigue, rash and other adverse reactions. Patients should have their liver function monitored regularly. If grade 3 or grade 4 adverse reactions occur (such as severe diarrhea, liver toxicity, etc.), the dose should be adjusted or medication should be restarted according to the doctor's advice.

4. Medication instructions for special groups

1. Pregnant and lactating women: Neratinib is embryotoxic and is contraindicated in pregnant women. Female patients should use effective contraception while using this drug and for at least 1 months after the last dose. Male patients whose sexual partners may become pregnant should avoid pregnancy during treatment and for at least 3Continue to use birth control pills during the next month. Breastfeeding women should stop breastfeeding during medication and at least1month after the last dose.

2. Children: The safety and effectiveness of neratinib in children have not been established and its use is not recommended.

5. Precautions for drug interactions

Neratinib interacts with many drugs, such as antacids. If you need to use other drugs while taking the medicine, please inform your doctor or pharmacist in time to avoid drug interactions.

In short, neratinib is an important drug in the treatment ofHER2 positive breast cancer, and its rational use is crucial to improving patient survival rate and quality of life. Patients should fully understand drug information before use, strictly follow medical instructions, use drugs rationally, and pay attention to monitoring adverse reactions to ensure the safety and effectiveness of treatment. If you have any questions or discomfort, please consult your doctor promptly.

At present, neratinib has been launched in the Chinese market, and patients can enjoy partial medical insurance reimbursement. At the same time, generic drugs of neratinib produced by Yaopin International are also available in the Bangladeshi market, providing patients with more choices. Patients should obtain this drug through formal channels according to their own needs.